Insulin Lispro Dosing
For prandial (mealtime) insulin dosing, initiate insulin lispro at 4 units per meal or 10% of the basal insulin dose, administered 0-2 minutes before eating, and titrate by 1-2 units or 10-15% twice weekly based on postprandial glucose targets. 1
Initial Dosing Strategy
When adding prandial insulin lispro to an existing basal insulin regimen:
- Starting dose: 4 units per day OR 10% of current basal insulin dose 1, 2
- Timing: Inject 0-2 minutes before the meal 3
- Initial approach: Begin with the largest meal or the meal causing the greatest postprandial glucose excursion 1, 2
Important Consideration at Initiation
When adding prandial insulin, reduce basal insulin by 4 units per day or 10% of the basal dose if HbA1c is <8% (<64 mmol/mol) to prevent hypoglycemia 1. This prevents insulin stacking and reduces hypoglycemia risk.
Titration Protocol
Increase the dose by 1-2 units or 10-15% twice weekly until postprandial glucose targets are achieved 1, 2. This evidence-based titration schedule balances efficacy with safety.
Hypoglycemia Management During Titration
- If hypoglycemia occurs, determine the cause
- If no clear precipitant identified, reduce the corresponding insulin dose by 10-20% 1, 2
- Monitor more frequently in patients with renal or hepatic impairment, as they face increased hypoglycemia risk 3
Intensification to Multiple Daily Injections
If glycemic targets remain unmet with single prandial dose:
- Add stepwise additional injections to cover other meals 1, 2
- Progress from one injection → two injections → three injections (full basal-bolus regimen)
- Each new prandial dose follows the same initiation principles: 4 units or 10% of basal dose
Alternative Approach with NPH Combination
For patients requiring more basal coverage throughout the day, lispro can be combined with NPH at mealtimes in approximate ratios of:
This approach reduces interprandial hyperglycemia while maintaining postprandial control. Research demonstrates this combination reduces hypoglycemia frequency and improves glucose variability compared to regular insulin regimens 4, 5.
Special Populations
Pediatric Patients (≥1 year)
- Same dosing principles apply 3
- Monitor injection sites more closely as pediatric patients experience higher rates of injection site reactions 3
- Consider switching to alternative insulin if persistent site reactions occur
Renal and Hepatic Impairment
- More frequent dose adjustments and glucose monitoring required 3
- Insulin requirements typically reduced in these populations
- Start conservatively and titrate cautiously
Geriatric Patients
- No dose adjustment needed based on age alone 3
- Standard dosing protocols apply
Common Pitfalls to Avoid
- Therapeutic inertia: Reassess and modify treatment every 3-6 months 1
- Overbasalization: Watch for clinical signals including basal doses >0.5 units/kg/day, elevated bedtime-to-morning glucose differentials, or hypoglycemia 1, 2. These indicate need for prandial insulin rather than further basal increases.
- Insulin stacking: The rapid onset and shorter duration of lispro (peak ~1 hour, duration ~4 hours) reduces but doesn't eliminate stacking risk—ensure bolus calculators account for insulin-on-board 6
- Timing errors: Unlike regular insulin requiring 20-40 minute pre-meal administration, lispro's efficacy depends on 0-2 minute pre-meal injection 3, 4
Practical Considerations
Total daily insulin requirements typically remain stable when switching from regular insulin to lispro, but the distribution changes: approximately 30% less rapid-acting insulin at meals and 30% more basal/NPH insulin may be needed 4. This reflects lispro's more physiologic pharmacokinetic profile.
For continuous subcutaneous insulin infusion (CSII), lispro demonstrates similar or improved glycemic control versus multiple daily injections without increasing severe hypoglycemia rates 7.